Literature DB >> 7649192

Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

M Rahman1, T Holme, I Jönsson, A Krook.   

Abstract

An enzyme immunoassay (EIA) was used to determine the antibody response to different serotypes of lipopolysaccharide (LPS) antigens of Moraxella catarrhalis in adult patients with lower respiratory tract infections (LRTI). Moraxella catarrhalis was isolated from sputum or nasopharyngeal samples from 20 patients with LRTI. Sixteen of the isolates were serotype A, four were type B and none were type C. The antibody response to the different LPS serotypes was determined in paired sera from patients suffering from LRTI. In addition to the 20 patients with Moraxella catarrhalis isolated (Group 1), a group of seven patients with LRTI of unknown etiology (Group 2) and a group of ten patients with LRTI of known other bacterial etiology (Group 3) were selected for this study. An increase in antibody levels of > 1.5-fold (convalescent-/acute-phase serum) was recorded in approximately half of the patients, not only in the first group (Moraxella catarrhalis isolated) but also in the other two groups. However, in the first and second groups there was a correlation between an increase in antibody levels in the LPS EIA and in an EIA using whole bacterial cells as antigen. In the group of patients in whom Moraxella catarrhalis was isolated, the antibody response to LPS antigens was not serotype specific. The antibody response to type-A and type-B LPS was more predominant than the response to type-C LPS in most patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649192     DOI: 10.1007/bf02116522

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens.

Authors:  M Vaneechoutte; G Verschraegen; G Claeys; A M Van Den Abeele
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

2.  The molecular mechanism of phase variation of H. influenzae lipopolysaccharide.

Authors:  J N Weiser; J M Love; E R Moxon
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

Review 3.  Animal glycosphingolipids as membrane attachment sites for bacteria.

Authors:  K A Karlsson
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

Review 4.  Lipopolysaccharide nomenclature--past, present, and future.

Authors:  P J Hitchcock; L Leive; P H Mäkelä; E T Rietschel; W Strittmatter; D C Morrison
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

5.  Minimal criteria for identification of Moraxella (Branhamella) catarrhalis.

Authors:  I Jönsson; B Eriksson; A Krook
Journal:  APMIS       Date:  1990-10       Impact factor: 3.205

6.  Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood.

Authors:  D Goldblatt; M W Turner; R J Levinsky
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

7.  Ultrastructural study on the adherence of Branhamella catarrhalis to oropharyngeal epithelial cell.

Authors:  K Ahmed; N Rikitomi; T Nagatake; K Matsumoto
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

8.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Comparative immunochemistry of lipopolysaccharides from Branhamella catarrhalis strains.

Authors:  J S Fomsgaard; A Fomsgaard; N Høiby; B Bruun; C Galanos
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media.

Authors:  H Faden; J Hong; T Murphy
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

View more
  14 in total

1.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

3.  Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Katie J Edwards; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

Review 4.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

5.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.

Authors:  Xinan Jiao; Takashi Hirano; Yingchun Hou; Xin-Xing Gu
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.

Authors:  Dabin Ren; Shengqing Yu; Song Gao; Daxin Peng; Ronald S Petralia; Artur Muszynski; Russell W Carlson; John B Robbins; Chao-Ming Tsai; David J Lim; Xin-Xing Gu
Journal:  Vaccine       Date:  2011-04-16       Impact factor: 3.641

8.  Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum.

Authors:  A Zaleski; N K Scheffler; P Densen; F K Lee; A A Campagnari; B W Gibson; M A Apicella
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Identification of a 3-deoxy-D-manno-octulosonic acid biosynthetic operon in Moraxella catarrhalis and analysis of a KdsA-deficient isogenic mutant.

Authors:  Nicole R Luke; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies.

Authors:  Johanna M Schwingel; Katie J Edwards; Andrew D Cox; Hussein Masoud; James C Richards; Frank St Michael; Carmen D Tekwe; Sanjay Sethi; Timothy F Murphy; Anthony A Campagnari
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.